On March 25, 2025 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), reported abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois (Press release, ADC Therapeutics, MAR 25, 2025, View Source [SID1234651431]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to present preclinical data on our exatecan-based Claudin-6, PSMA, and ACST2-targeting antibody-drug conjugates," said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics. "These ADCs hold promise for targeted cancer treatment in a broad range of cancer types, and we are pleased to have the opportunity to share our learnings across select solid tumors where there remains unmet need."
Details of ADC Therapeutics’ oral presentation at AACR (Free AACR Whitepaper) are as follows:
Title: Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models
Abstract: 1163
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutic Agents
Date and Time: Sunday, April 27, 2025, 3:00-5:00 p.m. CT
Presenter: Chris Pickford, Head of Clinical Research, ADC Therapeutics
Details of ADC Therapeutics’ poster presentations at AACR (Free AACR Whitepaper) are as follows:
Title: Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer
Abstract: 6736
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 4
Date and Time: Wednesday, April 30, 2025, 9:00 a.m. – 12:00 p.m. CT
Presenter: Ben Leatherdale, Senior Scientist, ADC Therapeutics
Title: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers
Abstract: 1580
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 1
Date and Time: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CT
Presenter: Danilo Cucchi, Senior Scientist, ADC Therapeutics